Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma

We aimed to investigate the radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma in real‐world practice.

[1]  M. Kurosaki,et al.  Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  M. Kudo,et al.  Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study , 2019, Cancers.

[3]  M. Imamura,et al.  Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib , 2019, Oncology.

[4]  J. Llovet,et al.  Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. , 2019, Journal of hepatology.

[5]  Y. Hiasa,et al.  Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. , 2019, Endocrine journal.

[6]  M. Kudo,et al.  Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis , 2019, Cancer medicine.

[7]  Hiroki Sato,et al.  Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma , 2019, World journal of gastroenterology.

[8]  M. Kudo,et al.  Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  M. Omata,et al.  The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting , 2019, Hepatology International.

[10]  Y. Hiasa,et al.  Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis , 2018, Cancer medicine.

[11]  M. Kudo.  Systemic Therapy for Hepatocellular Carcinoma: Latest Advances , 2018, Cancers.

[12]  S. Kaneko,et al.  Optimal management of patients with hepatocellular carcinoma treated with lenvatinib , 2018, Expert opinion on drug safety.

[13]  Y. Hiasa,et al.  Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  M. Kudo.  Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma , 2018, Liver Cancer.

[15]  J. Llovet,et al.  Molecular therapies and precision medicine for hepatocellular carcinoma , 2018, Nature Reviews Clinical Oncology.

[16]  H. Marusawa,et al.  Novel approaches for molecular targeted therapy against hepatocellular carcinoma , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  P. Galle,et al.  The role of molecular enrichment on future therapies in hepatocellular carcinoma. , 2018, Journal of hepatology.

[18]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[19]  M. Kudo,et al.  Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. , 2017, Journal of hepatology.

[20]  Sung-Bae Kim,et al.  Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer , 2016, The Journal of clinical endocrinology and metabolism.

[21]  M. Kudo,et al.  Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma , 2016, Journal of Gastroenterology.

[22]  K. Hayashi,et al.  Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma , 2016, Oncology.

[23]  H. Ueno,et al.  Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma , 2015, Clinical Cancer Research.

[24]  K. Hayashi,et al.  Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma , 2015, PloS one.

[25]  Z. Dezső,et al.  Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage , 2014, Vascular cell.

[26]  R. Lencioni,et al.  Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma , 2014, Liver Cancer.

[27]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[28]  M. Kurosaki,et al.  Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma , 2011, Oncology.

[29]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[30]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.